2019
Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC).
Cohen D, Medina B, Du K, Coveler A, Manji G, Oberstein P, Perna S, Miller G. Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC). Journal Of Clinical Oncology 2019, 37: tps4163-tps4163. DOI: 10.1200/jco.2019.37.15_suppl.tps4163.Peer-Reviewed Original ResearchStereotactic body radiotherapyImmune suppressionResection rateUnacceptable toxicityEfficacy of SBRTPhase II multi-institutional studySingle-arm phase II studyAdvanced unresectable pancreatic cancerArm phase II studyHigher R0 resection rateAdaptive immune suppressionImmune suppressive phenotypeM-CSFPD-1 blockadePhase II studyR0 resection rateStandard induction chemotherapyUnresectable pancreatic cancerSurgical resection rateAnti-tumor responseT cell populationsEfficacy of RTPlacement of fiducialsPre-clinical modelsMulti-institutional study
1992
Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.
Vosburgh E. Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse. Leukemia 1992, 6: 608-10. PMID: 1602800.Peer-Reviewed Case Reports and Technical NotesConceptsPulmonary leukostasisComplete remissionFirst relapseStandard induction chemotherapyRetinoic acid syndromeRetinoic acidAcute promyelocytic leukemiaAcute promyelocytic leukemia cellsTrans retinoic acidInduction chemotherapyResistant diseaseSignificant leukocytosisClinical trialsLeukostasisPromyelocytic leukemiaPromyelocytic leukemia cellsMature neutrophilsPatientsLeukemia cellsRelapseHigh rateOverall toxicityDe novoRemissionLeukocytosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply